Dr. Pieter Cullis – HC2018
Professor, Biochemistry and Molecular Biology, UBC
Dr. Pieter R. Cullis, PhD is a professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia, co-founder and co-chair of the Personalized Medicine Initiative, and director of the NanoMedicines Research Group at UBC. He has co-founded numerous companies and organisations, including Lipex Biomembranes Inc., Arbutus Biopharma, Northern Lipids Inc. (now Evonik), Acuitas Therapeutics and Precision NanoSystems, and the Centre for Drug Research and Development, where he was Founding Scientific Director from 2004 – 2010.
Cullis has contributed to fundamental advances in the generation, loading and targeting of lipid nanoparticle (LNP) systems for intravenous delivery of small molecule and macromolecular drugs. This work has contributed to three approved LNP products for the treatment of cancer and its complications and a fourth gene therapy drug to treat an hereditary condition that recently completed a most successful Phase 3 trial. He also works to influence the health care system to introduce personalized medicine based on molecular makeup of the individual and their disease.
Cullis has received numerous awards. He was elected as a Fellow of the Royal Society of Canada in 2004 and received the Journal of Drug Targeting’s Lifetime Achievement Award in 2016.
Dr. Pieter R. Cullis, PhD is a professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia, co-founder and co-chair of the Personalized Medicine Initiative, and director of the NanoMedicines Research Group at UBC. He has co-founded numerous companies and organisations, including Lipex Biomembranes Inc., Arbutus Biopharma, Northern Lipids Inc. (now Evonik), Acuitas Therapeutics and Precision NanoSystems, and the Centre for Drug Research and Development, where he was Founding Scientific Director from 2004 – 2010.
Cullis has contributed to fundamental advances in the generation, loading and targeting of lipid nanoparticle (LNP) systems for intravenous delivery of small molecule and macromolecular drugs. This work has contributed to three approved LNP products for the treatment of cancer and its complications and a fourth gene therapy drug to treat an hereditary condition that recently completed a most successful Phase 3 trial. He also works to influence the health care system to introduce personalized medicine based on molecular makeup of the individual and their disease.
Cullis has received numerous awards. He was elected as a Fellow of the Royal Society of Canada in 2004 and received the Journal of Drug Targeting’s Lifetime Achievement Award in 2016.
